Urinary Incontinence – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：78頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Urinary Incontinence – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Urinary Incontinence - Pipeline Review, H2 2012', provides an overview of the Urinary Incontinence therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. 'Urinary Incontinence - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Urinary Incontinence.
- A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Urinary Incontinence pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Urinary Incontinence therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Urinary Incontinence - Pipeline Review, H2 2012', provides an overview of the Urinary Incontinence therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. 'Urinary Incontinence - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Urinary Incontinence.
- A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Urinary Incontinence pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Urinary Incontinence therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Urinary Incontinence Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Urinary Incontinence 9
Urinary Incontinence Therapeutics under Development by Companies 11
Urinary Incontinence Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Urinary Incontinence Therapeutics – Products under Development by Companies 19
Urinary Incontinence Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Urinary Incontinence Therapeutics Development 22
Cook Medical Incorporated 22
Allergan, Inc. 23
Astellas Pharma Inc. 24
Mitsubishi Tanabe Pharma Corporation 25
Recordati S.p.A. 26
Addex Pharmaceuticals 27
Evotec Aktiengesellschaft 28
Plethora Solutions Holdings plc 29
KeyNeurotek Pharmaceuticals AG 30
Celogos 31
FemmePharma Global Healthcare, Inc. 32
Pierre Fabre Medicament 33
Beech Tree Labs, Inc. 34
Urinary Incontinence – Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
Betanis - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
P2X3 and P2X2/3 Antagonist - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ADX71943 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RCD-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
REC 0422 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
REC 1819 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
TT-138 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Solista - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PSD503 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KN203 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Botox - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AGN-214868 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
THVD-201 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ICES13 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
UISH001 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Autologous Muscle Derived Cells Transplantation - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Autologous Muscle Derived Cells Transplantation - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
V0162 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Urinary Incontinence Therapeutics – Drug Profile Updates 64
Urinary Incontinence Therapeutics – Discontinued Products 67
Urinary Incontinence Therapeutics - Dormant Products 69
Urinary Incontinence – Product Development Milestones 71
Featured News & Press Releases 71
Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference 71
Sep 15, 2011: Astellas Pharma Launches Betanis Tablet In Japan 71
Aug 24, 2011: Allergan Receives FDA Approval For Botox For Treatment Of Urinary Incontinence In Adults With Neurological Conditions 71
May 17, 2011: Astellas Announces Positive Phase III Results Showing Mirabegron Improves Key Overactive Bladder Symptoms 73
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 74
Apr 13, 2011: Beech Tree Labs Initiates Urinary Incontinence Trial 74
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 74
Mar 21, 2011: Astellas Announces Encouraging Results From Phase III Study of Mirabegron In OAB 75
Oct 18, 2010: Warner Chilcott Completes Acquisition of U.S. Rights to Enablex Overactive Bladder Treatment for $400 Million in Cash 76
Sep 24, 2010: Novartis sells US rights to the overactive bladder treatment Enablex 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78
List of Tables
Number of Products Under Development for Urinary Incontinence, H2 2012 9
Products under Development for Urinary Incontinence – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Development by Companies, H2 2012 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Development by Companies, H2 2012 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2012 21
Cook Medical Incorporated, H2 2012 22
Allergan, Inc., H2 2012 23
Astellas Pharma Inc., H2 2012 24
Mitsubishi Tanabe Pharma Corporation, H2 2012 25
Recordati S.p.A., H2 2012 26
Addex Pharmaceuticals, H2 2012 27
Evotec Aktiengesellschaft, H2 2012 28
Plethora Solutions Holdings plc, H2 2012 29
KeyNeurotek Pharmaceuticals AG, H2 2012 30
Celogos, H2 2012 31
FemmePharma Global Healthcare, Inc., H2 2012 32
Pierre Fabre Medicament, H2 2012 33
Beech Tree Labs, Inc., H2 2012 34
Assessment by Monotherapy Products, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 39
Urinary Incontinence Therapeutics – Drug Profile Updates 64
Urinary Incontinence Therapeutics – Discontinued Products 67
Urinary Incontinence Therapeutics – Discontinued Products (Contd..1) 68
Urinary Incontinence Therapeutics – Dormant Products 69
Urinary Incontinence Therapeutics – Dormant Products (Contd..1) 70
List of Figures
Number of Products under Development for Urinary Incontinence, H2 2012 9
Products under Development for Urinary Incontinence – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 35
Assessment by Route of Administration, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Molecule Type, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 39
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Urinary Incontinence Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Urinary Incontinence 9
Urinary Incontinence Therapeutics under Development by Companies 11
Urinary Incontinence Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Urinary Incontinence Therapeutics – Products under Development by Companies 19
Urinary Incontinence Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Urinary Incontinence Therapeutics Development 22
Cook Medical Incorporated 22
Allergan, Inc. 23
Astellas Pharma Inc. 24
Mitsubishi Tanabe Pharma Corporation 25
Recordati S.p.A. 26
Addex Pharmaceuticals 27
Evotec Aktiengesellschaft 28
Plethora Solutions Holdings plc 29
KeyNeurotek Pharmaceuticals AG 30
Celogos 31
FemmePharma Global Healthcare, Inc. 32
Pierre Fabre Medicament 33
Beech Tree Labs, Inc. 34
Urinary Incontinence – Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
Betanis - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
P2X3 and P2X2/3 Antagonist - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ADX71943 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RCD-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
REC 0422 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
REC 1819 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
TT-138 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Solista - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PSD503 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KN203 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Botox - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AGN-214868 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
THVD-201 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ICES13 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
UISH001 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Autologous Muscle Derived Cells Transplantation - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Autologous Muscle Derived Cells Transplantation - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
V0162 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Urinary Incontinence Therapeutics – Drug Profile Updates 64
Urinary Incontinence Therapeutics – Discontinued Products 67
Urinary Incontinence Therapeutics - Dormant Products 69
Urinary Incontinence – Product Development Milestones 71
Featured News & Press Releases 71
Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference 71
Sep 15, 2011: Astellas Pharma Launches Betanis Tablet In Japan 71
Aug 24, 2011: Allergan Receives FDA Approval For Botox For Treatment Of Urinary Incontinence In Adults With Neurological Conditions 71
May 17, 2011: Astellas Announces Positive Phase III Results Showing Mirabegron Improves Key Overactive Bladder Symptoms 73
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 74
Apr 13, 2011: Beech Tree Labs Initiates Urinary Incontinence Trial 74
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 74
Mar 21, 2011: Astellas Announces Encouraging Results From Phase III Study of Mirabegron In OAB 75
Oct 18, 2010: Warner Chilcott Completes Acquisition of U.S. Rights to Enablex Overactive Bladder Treatment for $400 Million in Cash 76
Sep 24, 2010: Novartis sells US rights to the overactive bladder treatment Enablex 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78
List of Tables
Number of Products Under Development for Urinary Incontinence, H2 2012 9
Products under Development for Urinary Incontinence – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Development by Companies, H2 2012 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Development by Companies, H2 2012 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2012 21
Cook Medical Incorporated, H2 2012 22
Allergan, Inc., H2 2012 23
Astellas Pharma Inc., H2 2012 24
Mitsubishi Tanabe Pharma Corporation, H2 2012 25
Recordati S.p.A., H2 2012 26
Addex Pharmaceuticals, H2 2012 27
Evotec Aktiengesellschaft, H2 2012 28
Plethora Solutions Holdings plc, H2 2012 29
KeyNeurotek Pharmaceuticals AG, H2 2012 30
Celogos, H2 2012 31
FemmePharma Global Healthcare, Inc., H2 2012 32
Pierre Fabre Medicament, H2 2012 33
Beech Tree Labs, Inc., H2 2012 34
Assessment by Monotherapy Products, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 39
Urinary Incontinence Therapeutics – Drug Profile Updates 64
Urinary Incontinence Therapeutics – Discontinued Products 67
Urinary Incontinence Therapeutics – Discontinued Products (Contd..1) 68
Urinary Incontinence Therapeutics – Dormant Products 69
Urinary Incontinence Therapeutics – Dormant Products (Contd..1) 70
List of Figures
Number of Products under Development for Urinary Incontinence, H2 2012 9
Products under Development for Urinary Incontinence – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 35
Assessment by Route of Administration, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Molecule Type, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 39
